TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss (TQBSP)
Primary Purpose
Safety Issues, Efficacy, Self
Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
TQB3525
Sponsored by
About this trial
This is an interventional treatment trial for Safety Issues focused on measuring osteosarcoma, ewing sarcoma, chondrosarcoma, PI3KA mutation, PTEN loss, TQB3525
Eligibility Criteria
Inclusion Criteria:
- progression upon first-line chemotherapy;
- with target lesions according to RECIST 1.1;
- geno-profiling with PI3KA mutations or PTEN loss;
- ECOG PS status 0 or 1 with a life expectancy >3 months;
- adequate renal, hepatic, and hematopoietic function;
Exclusion Criteria:
- been previously exposed to other TKIs;
- had central nervous system metastasis;
- had other kinds of malignant tumors at the same time;
- had cardiac insufficiency or arrhythmia;
- had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine protein ≥ ++, and so on;
- had pleural or peritoneal effusion that needed to be handled by surgical treatment;
- had other infections or wounds;
- pregnant or breastfeeding.
Sites / Locations
- Peking University Shougang Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
TQB3525 arm
Arm Description
3+3 design for phase I for RP2D (Recommended Phase 2 Dose) for adolescents (12-17 years old) (15mg QD or 20mg QD); phase II for efficacy exploration for another 17 patients using RP2D QD
Outcomes
Primary Outcome Measures
toxicity profiles
according to CTCAE 5.0
Secondary Outcome Measures
progression free survival
from starting treatment to progression/death
overall survival
from starting treatment to death
Full Information
NCT ID
NCT04690725
First Posted
December 25, 2020
Last Updated
December 29, 2020
Sponsor
Peking University People's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04690725
Brief Title
TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss
Acronym
TQBSP
Official Title
Phase I Study of TQB3525, Phosphatidylinositol-3-Kinase α and δ Inhibitors, in Patients With Advanced Bone Sarcomas
Study Type
Interventional
2. Study Status
Record Verification Date
December 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 1, 2020 (Actual)
Primary Completion Date
January 1, 2022 (Anticipated)
Study Completion Date
June 1, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Peking University People's Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The PI3K, protein kinase B (AKT), and mTOR signaling network promotes cell growth, survival, metabolism, and motility, but becomes a critical oncogenic driver under aberrant conditions that control the tumor microenvironment and angiogenesis. The PI3K-AKT-mTOR axis is the most frequently deregulated signaling pathway in primary osteosarcoma and other bone tumors. PI3Ka has high rates of 25-50% activating mutations associated with tumor formation in osteosarcoma. Other causes of pathway hyperactivation include loss of function of the tumor suppressor PTEN, gain-of-function mutations in AKT and PDK1, or upregulation of receptor tyrosine kinases. TQB3525 is an orally bioavailable, potent, dual catalytic site inhibitor of PI3Ka and PI3Kd. Tumor growth inhibition has been demonstrated in multiple xenograft osteosarcoma models with PI3K-mutant, PTEN-null cell lines. The investigators try to investigate TQB3525 in primary osteosarcoma and other bone tumors for its safety, tolerability, dose-limiting toxicities (DLT), MTD and antitumor efficacy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Safety Issues, Efficacy, Self
Keywords
osteosarcoma, ewing sarcoma, chondrosarcoma, PI3KA mutation, PTEN loss, TQB3525
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Model Description
TQB3525 orally taken
Masking
None (Open Label)
Allocation
N/A
Enrollment
29 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
TQB3525 arm
Arm Type
Experimental
Arm Description
3+3 design for phase I for RP2D (Recommended Phase 2 Dose) for adolescents (12-17 years old) (15mg QD or 20mg QD); phase II for efficacy exploration for another 17 patients using RP2D QD
Intervention Type
Drug
Intervention Name(s)
TQB3525
Intervention Description
TQB3525 is an orally bioavailable, potent, class I kinase inhibitors of PI3Ka and PI3Kd.
Primary Outcome Measure Information:
Title
toxicity profiles
Description
according to CTCAE 5.0
Time Frame
6 months
Secondary Outcome Measure Information:
Title
progression free survival
Description
from starting treatment to progression/death
Time Frame
6 months
Title
overall survival
Description
from starting treatment to death
Time Frame
2 years
Other Pre-specified Outcome Measures:
Title
fasting triglyceride
Description
dynamic changes from Peripheral Blood
Time Frame
6 months
Title
fasting lipoprotein
Description
dynamic changes from Peripheral Blood
Time Frame
6 months
Title
fasting insulin
Description
dynamic changes from Peripheral Blood
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
progression upon first-line chemotherapy;
with target lesions according to RECIST 1.1;
geno-profiling with PI3KA mutations or PTEN loss;
ECOG PS status 0 or 1 with a life expectancy >3 months;
adequate renal, hepatic, and hematopoietic function;
Exclusion Criteria:
been previously exposed to other TKIs;
had central nervous system metastasis;
had other kinds of malignant tumors at the same time;
had cardiac insufficiency or arrhythmia;
had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine protein ≥ ++, and so on;
had pleural or peritoneal effusion that needed to be handled by surgical treatment;
had other infections or wounds;
pregnant or breastfeeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wei Guo, Ph.D and M.D.
Organizational Affiliation
Chinese Sarcoma Study Group
Official's Role
Principal Investigator
Facility Information:
Facility Name
Peking University Shougang Hospital
City
Beijing
ZIP/Postal Code
100036
Country
China
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss
We'll reach out to this number within 24 hrs